Lupin gets USFDA nod for generic product
As per IQVIA MAT September 2021 data, Sevelamer Carbonate for Oral Suspension had estimated annual sales of USD 51.7 million in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 25, 2021 Category: Pharmaceuticals Source Type: news
Lupin gets USFDA nod to market generic Sevelamer Carbonate tablets
The product is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis, Lupin said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2021 Category: Pharmaceuticals Source Type: news
Glenmark Pharma gets USFDA nod for drug for patients on dialysis
The approved product is a generic version of Genzyme Corporation's Renagel tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 11, 2019 Category: Pharmaceuticals Source Type: news
Dr Reddy's launches oral suspension drug in the US market
The newly launched product is in the strengths of 0.8 g and 2.4 g packets, and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 27, 2018 Category: Pharmaceuticals Source Type: news
Amneal Brings Generic for Renvela(R) to Market and Starts December Strong with Six Product Launches
BRIDGEWATER, N.J., Dec. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals LLC has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. The Amneal generic is an AB-rated therapeutic equivalent to Renvela®. Mo... Biopharmaceuticals, Generics, Product Launch Amneal Pharmaceuticals, sevelamer, Renvela (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 20, 2017 Category: Pharmaceuticals Source Type: news
Cipla gets USFDA nod for generic version of Renvela tablets
The approved product is a generic equivalent to the reference listed drug (RLD), Renvela tablets, 800 mg of Genzyme Corporation, said Cipla. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 27, 2017 Category: Pharmaceuticals Source Type: news
Aurobindo Pharma gets USFDA nod for oral suspension
Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2017 Category: Pharmaceuticals Source Type: news
10 Little-Known Tips For Saving Money On Health Care
Sometimes, the devil is in the details. That’s a rule that applies to health care as well; the more you know, the better off you will be. Here are 10 ways you might be surprised to know you can save money on the one truly priceless thing you have: your health.
1. Prescriptions may cost you less if you don’t use your insurance.
As difficult a pill as this is to swallow, your best deal on some commonly prescribed drugs may be found by ignoring the drug coverage you pay for and instead just reaching for your wallet. Often, your insurance drug plan requires a copay that is higher than the cost of paying cash at the...
Source: Healthy Living - The Huffington Post - February 1, 2017 Category: Consumer Health News Source Type: news
Renagel (Sevelamer Hcl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 12, 2016 Category: Drugs & Pharmacology Source Type: news
Renvela (Sevelamer Carbonate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 12, 2016 Category: Drugs & Pharmacology Source Type: news
New Phosphate Binder for Renal Failure Lowers Pill BurdenNew Phosphate Binder for Renal Failure Lowers Pill Burden
The investigational drug controls hyperphosphatemia in patients with renal failure and requires fewer daily doses than sevelamer carbonate, but it has more gastrointestinal adverse effects. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news
Phase III data for ferric citrate (Zerenex®) for hyperphosphataemia
Source: BioSpace
Area: News
BioSpace has reported on data from a Phase III study evaluating the safety and efficacy of ferric citrate (Zerenex®) in the treatment of hyperphosphataemia in patients with end-stage renal disease (ESRD) on dialysis (n=441).
Following a two-week washout, patients were randomised 2:1 to receive either ferric citrate or sevelamer carbonate (Renvela®) and/or calcium acetate (Phoslo®) during a 52-week safety assessment period. Following this, subjects initially randomised to ferric citrate were re-randomised to either continue treatment or switch to placebo for a 4-week efficacy ass...
Source: NeLM - News - January 29, 2013 Category: Drugs & Pharmacology Source Type: news
